Navigation Links
Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
Date:6/13/2010

UNION CITY, Calif., June 11 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has received notification from the U.S. Food & Drug Administration (FDA) that the PDUFA date for Questcor's supplemental new drug application (sNDA) to approve Acthar for the treatment of infantile spasms (IS) has been extended to September 11, 2010.  The FDA extended the PDUFA date in order to review information regarding labeling and potential post-approval commitments that they solicited from Questcor. This follows the May 6, 2010 votes by the Advisory Committee to the Division of Peripheral and Central Nervous System Drugs of the FDA which indicated support for approval of this new Acthar indication.  

"We look forward to working with the FDA over the next few months in order to finalize these critical elements," said Don M. Bailey, President and CEO of Questcor.

Investors should note that there can be no assurance that the FDA will approve this sNDA by September 11, 2010, or thereafter.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
2. Trading Halted Today in Questcor Pharmaceuticals Common Stock
3. Questcor to Discuss Results From FDA Panel Meeting
4. Questcor Reports Solid Fourth Quarter Results
5. Mylan Receives Approval for Generic Version of Neurontin® Tablets
6. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
7. Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension
8. Amedica® Receives Patent for Hip Implant Using Monoblock Ceramic Technology
9. The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup
10. PolyGel® Receives SADMERC Approval for L-Code L0627 for New ThermoActive™ Plus Cold & Hot Compression Lumbar Orthosis
11. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016 Sangamo BioSciences, Inc. (Nasdaq: ... announced the presentation of preclinical and manufacturing data that support ... 58 th Annual Meeting of the American Society of ... , from December 3-6, 2016. "We have ... A which we believe is highly competitive, and we remain ...
(Date:12/5/2016)... Dec. 5, 2016  Parallax Health Sciences, Inc. ("Parallax" ... announce that its pharmaceutical business, RoxSan Pharmacy, Inc. has ... coverage in all of the 42 states it is ... Michael Rashti Pharm . D, Pharmacist in Charge ... for our business. Medicare B spending last year came ...
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. ... the Commercialization of Public Research (the Florida ... funding agreement SegAna, LLC, an Orlando ... of Central Florida. The Florida Institute supports new ... early funding gaps for companies spinning out of Florida-based ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... ... The Touchpoint Solution’s new neuroscience wearable, Buzzies, generated over $100K in sales online ... $25,000 on Kickstarter to bring to the market what people are calling ... inventor, says she feels like she stumbled upon a miracle that she wants other ...
(Date:12/6/2016)... ... ... Of the variety of ingredients in the food supply, few spark more ... beliefs that hot dogs include “everything but the oink,” today’s wieners are made from ... meat and poultry in a hot dog recipe can add flavor, keep hot dogs ...
(Date:12/6/2016)... ... December 06, 2016 , ... Public middle and high schools ... apply for a 2016/2017 California Casualty Thomas R. Brown Athletics Grant. The application ... receive up to $3,000. , The grant is named after California Casualty ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... charity, is thrilled to formally announce its Not a Moment to Lose fundraising ... Lose will rally supporters dedicated to declaring victory over cancer. The campaign aims ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
Breaking Medicine News(10 mins):